These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 17085373

  • 1. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies.
    Shapiro S.
    Climacteric; 2006 Dec; 9(6):416-20. PubMed ID: 17085373
    [Abstract] [Full Text] [Related]

  • 2. Recent epidemiological evidence relevant to the clinical management of the menopause.
    Shapiro S.
    Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
    [Abstract] [Full Text] [Related]

  • 3. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [Abstract] [Full Text] [Related]

  • 4. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S.
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [Abstract] [Full Text] [Related]

  • 5. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H, Stevenson J.
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [Abstract] [Full Text] [Related]

  • 6. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, Women's Health Initiative Investigators.
    Am J Epidemiol; 2006 Apr 01; 163(7):589-99. PubMed ID: 16484450
    [Abstract] [Full Text] [Related]

  • 7. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
    Lemay A.
    J Obstet Gynaecol Can; 2002 Sep 01; 24(9):711-5. PubMed ID: 12360366
    [Abstract] [Full Text] [Related]

  • 8. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
    Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, Women's Health Initiative Investigators.
    Am J Epidemiol; 2005 Sep 01; 162(5):404-14. PubMed ID: 16033876
    [Abstract] [Full Text] [Related]

  • 9. Oral contraceptives, hormone therapy and cardiovascular risk.
    Shapiro S.
    Climacteric; 2008 Oct 01; 11(5):355-63. PubMed ID: 18781479
    [Abstract] [Full Text] [Related]

  • 10. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA.
    Climacteric; 2007 Oct 01; 10 Suppl 2():27-31. PubMed ID: 17882669
    [Abstract] [Full Text] [Related]

  • 11. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP.
    Am J Obstet Gynecol; 2004 Apr 01; 190(4):1141-67. PubMed ID: 15118656
    [Abstract] [Full Text] [Related]

  • 12. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators.
    N Engl J Med; 2003 Aug 07; 349(6):523-34. PubMed ID: 12904517
    [Abstract] [Full Text] [Related]

  • 13. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun 07; 13(71):106-9. PubMed ID: 15233153
    [Abstract] [Full Text] [Related]

  • 14. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

  • 15. A clinician's review of the WHI-related literature.
    Speroff L.
    Int J Fertil Womens Med; 2004 Sep 16; 49(6):252-67. PubMed ID: 15751264
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM, Naftolin F, Brinton EA, Judelson DR.
    Ann N Y Acad Sci; 2005 Jun 16; 1052():43-56. PubMed ID: 16024750
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.